No Data
No Data
Avidity Gets FDA Partial Clinical Hold Lifted on DM1 Drug Candidate
PepGen Inc. Board Reshuffles as Ashton Plans Retirement
Express News | PepGen Inc - Adopted Resolution as of Sept 18, Decreasing Size of Board From Seven Directors to Six Directors
PepGen Announces Christopher Ashton, PhD, to Retire From Its Board of Directors
Express News | PepGen Announces Christopher Ashton, Phd, to Retire From Its Board of Directors
Express News | PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) to Newly Appointed Executive Vice President, Research & Development